T. Rowe Price Associates’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,209
| Closed | -$28K | – | 2946 |
|
|
2024
Q1 | $28K | Buy |
1,209
+84
| +7% | +$1.95K | ﹤0.01% | 2916 |
|
|
2023
Q4 | $22K | Buy |
1,125
+125
| +13% | +$2.44K | ﹤0.01% | 2867 |
|
|
2023
Q3 | $18K | Sell |
1,000
-940
| -48% | -$16.9K | ﹤0.01% | 2849 |
|
|
2023
Q2 | $59K | Buy |
1,940
+1,000
| +106% | +$30.4K | ﹤0.01% | 2780 |
|
|
2023
Q1 | $28K | Buy |
940
+44
| +5% | +$1.31K | ﹤0.01% | 2835 |
|
|
2022
Q4 | $18K | Hold |
896
| – | – | ﹤0.01% | 2878 |
|
|
2022
Q3 | $28K | Hold |
896
| – | – | ﹤0.01% | 2890 |
|
|
2022
Q2 | $21K | Buy |
896
+60
| +7% | +$1.41K | ﹤0.01% | 2918 |
|
|
2022
Q1 | $37K | Buy |
836
+132
| +19% | +$5.84K | ﹤0.01% | 2929 |
|
|
2021
Q4 | $27K | Sell |
704
-80
| -10% | -$3.07K | ﹤0.01% | 2951 |
|
|
2021
Q3 | $40K | Buy |
784
+24
| +3% | +$1.22K | ﹤0.01% | 2905 |
|
|
2021
Q2 | $66K | Buy |
760
+344
| +83% | +$29.9K | ﹤0.01% | 2874 |
|
|
2021
Q1 | $19K | Hold |
416
| – | – | ﹤0.01% | 2835 |
|
|
2020
Q4 | $11K | Buy |
+416
| New | +$11K | ﹤0.01% | 2661 |
|